Thermo Fisher Q3 revenue, adjusted profit beat estimates after new product launches
TMO•Thermo Fisher reported third-quarter revenue of $12.14 billion, up 9%, and adjusted EPS of $6.68, up 15%; both beat analyst estimates. The company cited new product launches, its growth strategy and execution as drivers.
1. Quarterly results
Thermo Fisher's third-quarter revenue rose 9% to $12.14 billion, above the $11.95 billion analyst consensus. Adjusted EPS increased 15% to $6.68, beating the $6.40 estimate; adjusted net income was $2.48 billion versus the $2.38 billion consensus.
2. Products and strategy
The company said results were driven in part by launches including the Orbitrap Isora mass spectrometer, EMPAD G2 electron detector, EliA CTD 13 Screen autoimmune test and Ion 560 sequencing chip. It also cited efforts to strengthen its commercial engine and deepen customer partnerships, including initiatives with Mayo Clinic and an AI-Automation Innovation Center in South Korea.
3. Updated outlook ahead
Thermo Fisher said it will provide updated 2026 financial guidance during its earnings call.
